ACADIA Pharmaceuticals
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, ACADIA Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#473 of 15,742 sponsors by registered trial count).
ACADIA Pharmaceuticals: 35 sponsored US clinical trials, 3 recruiting.
ACADIA Pharmaceuticals sponsors 35 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 22 completed. 16 of these trials are in Phase 3-4 (later-stage) and 18 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Parkinson's Disease Psychosis, with 2 trials.
Top-decile sponsor footprint
ACADIA Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#473 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
22 of 31 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (71.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
35 total, page 1 of 1
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
NCT07284667
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
NCT07029581
ACP-204 in Adults With Alzheimer's Disease Psychosis
NCT06159673
Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
NCT06173531
Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder
NCT05555615
Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder
NCT05523895
An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome
NCT04988867
Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the Knee
NCT05008835
Evaluate the Efficacy and Safety of ACP-044 for the Treatment of Acute Postoperative Pain Following Bunionectomy
NCT04855240
Open-Label Extension Study of Trofinetide for Rett Syndrome
NCT04776746
Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis
NCT04292223
Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome
NCT04279314
Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)
NCT04181723
Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine
NCT04164758
Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
NCT04000009
Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
NCT03968159
Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease
NCT03623321
A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease
NCT03575052
Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression
NCT03482882
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
NCT03325556
The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study
NCT03152292
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
NCT03118947
Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
NCT03121586
Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)
NCT03018340
Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)
NCT02970305
Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)
NCT02992132
Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)
NCT02970292
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
NCT01174004
A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
NCT00658567
A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
NCT00550238
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
NCT00477672
ACP-104 in Acutely Psychotic Subjects With Schizophrenia
NCT00490516
Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone
NCT00361166
An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients
NCT01518309
Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug
NCT00087542
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 18 |
| Phase 3 | 15 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the ACADIA Pharmaceuticals pipeline
3 recruiting of 35 indexed (9% open); 22 completed (63%).
Phase mix: 16 late (III/IV) vs 18 early (I/II) (balanced across stages).
Top condition: Parkinson's Disease Psychosis (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
ACADIA Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 35 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
ACADIA Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 35 trials (± recruiting share)
- INSYS Therapeutics · 35 trials · 0% recruiting
- Merz North America · 35 trials · 3% recruiting
- Palo Alto Veterans Institute for Research · 35 trials · 20% recruiting
- Philips Respironics · 35 trials · 0% recruiting
Sponsors near 9% open enrollment (± trial volume)
- Texas Tech University Health Sciences Center, El Paso · 9% recruiting · 35 trials
- National Institute of Neurological Disorders and Stroke (NINDS) · 8% recruiting · 567 trials
- AMAG Pharmaceuticals · 9% recruiting · 23 trials
- Iowa State University · 9% recruiting · 23 trials
Related
What to do with this ACADIA Pharmaceuticals page
35 registered trials is a research-attention snapshot, not an endorsement of ACADIA Pharmaceuticals or any single study.
- 3 of ACADIA Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Parkinson's Disease Psychosis is the condition ACADIA Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Parkinson's Disease Psychosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
ACADIA Pharmaceuticals pipeline card: 35 registered trials from official public datasets.Report a data error.